Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.49 |
| ▸ | CDC42 | P60953 | 1/20 | 0.49 |
| ▸ | RAC1 | P63000 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | NNMT | P40261 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | OXTR | P30559 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069855 | 1.00 | PTGS2 (0.49) | PTGS2AKR1C3PTGS1AKR1C2TSHR | |
| SCHEMBL1515561 | 0.85 | NNMT (0.56) | NNMTCHRNA7KMT2AALDH1A1POLB | |
| SCHEMBL3550308 | 0.84 | KMT2A (0.52) | NNMTCHRNA7KMT2AALDH1A1POLB | |
| SCHEMBL10317483 | 0.83 | NPSR1 (0.49) | TSHRNNMTCHRNA7KMT2AALDH1A1 | |
| SCHEMBL10318613 | 0.83 | NPSR1 (0.49) | TSHRNNMTCHRNA7KMT2AALDH1A1 | |
| SCHEMBL24853397 | 0.82 | ACACB (0.41) | PTGS2AKR1C3PTGS1AKR1C2TSHR | |
| SCHEMBL30340509 | 0.82 | ACACB (0.41) | PTGS2AKR1C3PTGS1AKR1C2TSHR | |
| SCHEMBL2388678 | 0.81 | NNMT (0.47) | NNMTCHRNA7KMT2AALDH1A1POLB | |
| SCHEMBL7082182 | 0.81 | NNMT (0.47) | AKR1C3AKR1C2NNMTCHRNA7KMT2A | |
| SCHEMBL11410948 | 0.81 | PTGS1 (0.55) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118666764-A | Triazole amide compound, preparation method and application thereof | 中国人民解放军海军军医大学 | 2024-09-20 | — | — | CN | disclosed |
| CN-114478519-B | Pyrazolopyridine compound or salt thereof, and preparation method and application thereof | 励缔(杭州)医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-114478519-A | Pyrazolopyridine compound or salt thereof, and preparation method and application thereof | 上海辉启生物医药科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2022083741-A1 | PYRAZOLOPYRIDINE COMPOUND OR SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海辉启生物医药科技有限公司 | 2022-04-28 | — | — | WO | disclosed |
| WO-2011160918-A1 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-12-29 | — | — | WO | disclosed |
| US-7074930-B2 | Amine salts of an integrin receptor antagonist | MERCK & CO., INC (US) | 2006-07-11 | — | — | US | disclosed |
| EP-1444231-A4 | AMINE SALTS OF AN INTEGRIN RECEPTOR ANTAGONIST | MERCK & CO INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20040249158-A1 | Amine salts of an integrin receptor antagonist | MERCK & CO., INC. | 2004-12-09 | — | — | US | disclosed |
| EP-1444231-A1 | AMINE SALTS OF AN INTEGRIN RECEPTOR ANTAGONIST | Merck & Co., Inc. (US) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040143-A1 | AMINE SALTS OF AN INTEGRIN RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| US-4649141-A | HISTAMINE ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1987-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249158-A1 | Amine salts of an integrin receptor antagonist | ITGB3, ITGA1, ITGAL | PTGS2 2715/4885AKR1C3 699/4885PTGS1 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.